DNB THESIS : Thyroid dysfunction in patients treated with Radiotherapy / Chemo-Radiotherapy for non- thyroid head & neck cancers.
WORKSHOPS ATTENDED
- Workshop and Hands-on Training on High Precision Radiation at Apollo Speciality Hospitals , Chennai, January 2004.
- Workshop on Bench to Bedside held at Kidwai Memorial Institute of Oncology, Bangalore, October 2004.
- Investigator's Meet for a Clinical trial on Deforolimus at Prague, Czech Republic - “A randomized phase II trial of deforolimus (AP 23573; MK – 8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy.”
PAPERS PRESENTED
- Proffered paper in the 23rd State Annual AROI Conference Tamil Nadu & Pondicherry chapter, 2008 and was awarded the BEST PAPER PRIZE for the paper titled “Thyroid dysfunction in patients treated with radiotherapy/ chemo-radiotherapy for non-thyroid head & neck cancers.”
- Proffered paper in 29th Annual National AROICON 2007 ( Association of Radiation Oncologists of India Conference ) titled “Thyroid dysfunction in patients treated with Radiotherapy / Chemo- Radiotherapy for non-thyroid head & neck cancers.”
- Proffered paper in 19th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2003 (Association of Radiation Oncologists of India Conference ) titled “ Rare case presentation – A case of solitary plasmacytoma of occipital bone .”
- Poster presentation in 24th National AROICON 2002 ( Association of Radiation Oncologists of India Conference ).
CONFERENCES ATTENDED
- 24th National AROICON 2002 ( Association of Radiation Oncologists of India Conference ).
- 26th National AROICON 2004 ( Association of Radiation Oncologists of India Conference ).
- 29th National AROICON 2007 ( Association of Radiation Oncologists of India Conference ).
- 11th Biennial Conference of Indian Society of Oncology and 13th Biennial Conference of Indian Society of Medical & Paediatric Oncology , October 2004.
- Multimodality Head & Neck Cancer Care symposium at Tata Memorial Hospital, Mumbai, Dec 2005.
- 18th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2002
- 19th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2003
- 20th State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2004
- 21st State Annual AROI Conference ( Tamilnadu & Pondicherry chapter ) 2005
- 23rd State Annual AROI Conference (Tamil Nadu & Pondicherry chapter) 2008
- 10th Annual Conference on Medical Physics and Radiation Safety, 2003.
- RGCON 2010 at Rajiv Gandhi Cancer Institute, New Delhi 26th - 28th March 2010
INVOLVEMENT IN CONFERENCES & CME PROGRAMMES
- Organising member , Oncoclub , July 2013; Focus - Radiology in Oncology
- Organising Member & Faculty, HOPE 2013, Trichy
- Organising member , Oncoclub , Feb 2014 ; Focus - Approach to Head and Neck Cancers
- Organising member , Oncoclub , Aug 2014; Focus - Neuro-Oncology
- Organising Member & Faculty, BRECON 2013, Trichy.
- Organising Member & Faculty, BRECON 2014, Trichy.
- Organising Member & Faculty, BRECON 2015, Trichy.
- Organising Member & Faculty, 8 th Tamilnadu Puducherry Padiatric Oncology Group(TPPOG) meet Feb,2016,Trichy
- Panelist at ICON Sept 2015 held at Coimbatore : Panel Discussion : Addressing Brain metastasis in Breast Ca & Lung cancer Is there a change in approach ? CLINICAL TRIALS : Gained experience as Clinical Trial Co-ordinator in following trials 1. Pharmanet STUDY NAME: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection Multikine® Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of Care Only. 2. Piramal ( SPARK ) An open label,multi center phase II study of Selective Cyclin Dependent Kinase InhibitorP276- 00 In Combination with Radiation In Subjects with Recurrent and/or Locally advanced Squamous Cell Carcinoma of Head and Neck (P276- 00/31/08) 3. Sanofi Aventis ; CRO - Icon A Mulitnational,Randomized,double- blind,placebo controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of Venous Thromboembolism(VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy(protocol EFC6521). 4. GeneMedix plc ; CRO - Reliance CRO Safety and Efficacy of Recombinant Human Granulocyte-colony Stimulating factor GCSF (ReliGrast tm or Neupogen R) in Patients with Chemotherapy induced Neutropenia. 5. Alder Biopharmaceuticals ; CRO- Veeda Oncology A Phase II Study to Determine the Safety, Efficacy and Pharmacokinetics of multiple Intravenous Doses of ALD518 80, 160 mg Versus Placebo Administrated to Patients with Non-small Cell Lung cancer- Related Fatigue and Cachexia. 6. Ariad pharmaceuticals ; CRO - Medpace A randomized phase II trial of deforolimus (AP 23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy. 7. Glaxosmithkline pharmaceuticals limited. A Phase III study of Erbb2 Positive Advanced Or Metastatic Gastric Or Esophageal Or Gastroesophageal junction Adenocarcenoma Treated With Capecitabine Plus Oxaliplatin With Or Without Lapatinib.”
